Continuation of ARBs in CKD Patients on Renal Replacement Therapy
ARBs can be safely continued in clinically stable hemodialysis patients without hypotension or hyperkalemia, though they carry a 2-fold increased risk of hyperkalemia that requires close monitoring. 1, 2
Evidence for Safety in Dialysis Patients
The available research demonstrates that ARBs do not cause additional hemodynamic instability or unmanageable hyperkalemia in stable hemodialysis patients:
A prospective crossover study of 69 hemodialysis patients found no significant difference in mean serum potassium levels between periods with and without ARB exposure (5.50 ± 0.66 mmol/L with ARB alone vs 5.54 ± 0.67 mmol/L without RAS blockade). 1
The incidence of severe hyperkalemia (>6.0 mmol/L) was actually numerically lower with ARB monotherapy (19.6%) compared to no RAS blockade (25.8%), though this difference was not statistically significant. 1
No patients discontinued ARBs due to hyperkalemia or complications during the 3-month study period. 1
Hyperkalemia Risk Requires Monitoring
While ARBs can be continued safely, they do increase hyperkalemia risk:
A large prospective study of 251 hemodialysis patients found that ARB use was associated with a 2.2-fold increased risk of hyperkalemia (OR = 2.2; 95% CI: 1.4-3.4). 2
This increased risk was present in both anuric patients (OR = 2.3) and those with residual renal function (OR = 2.1). 2
Anuric patients had significantly higher potassium levels compared to non-anuric patients (5.58 vs 5.19 mmol/L, P<0.001), warranting more cautious monitoring. 1
Clinical Outcomes Favor Continuation
Discontinuing ARBs after hyperkalemia is associated with worse outcomes than continuation:
In a population-based cohort study of 78,490 CKD patients with hyperkalemia, ARB discontinuation was associated with 32-47% higher all-cause mortality (Manitoba: HR 1.32; Ontario: HR 1.47) and 28-32% higher cardiovascular mortality. 3
ARB discontinuation was also associated with 11-65% increased risk of dialysis initiation (Manitoba: HR 1.65; Ontario: HR 1.11). 3
Guideline-Based Approach to Continuation
The KDIGO guidelines provide clear criteria for when to continue versus discontinue ARBs in dialysis patients:
Continue ARBs if:
- The patient is clinically stable without symptomatic hypotension 4
- Hyperkalemia is absent or manageable with potassium-lowering interventions 4, 5
- No uremic symptoms requiring palliation are present 4, 5
Consider discontinuation only if:
- Symptomatic hypotension develops that does not respond to volume optimization 4, 5
- Uncontrolled hyperkalemia persists despite dietary restriction, diuretic optimization, and potassium binders 4, 5
- Uremic symptoms require palliation in the setting of eGFR <15 ml/min/1.73 m² 4, 5
Monitoring Protocol for Dialysis Patients
Check serum potassium monthly with predialysis laboratory draws when ARBs are continued in hemodialysis patients. 2
More frequent monitoring (every 1-2 weeks) is warranted for anuric patients or after dose adjustments. 1
Review concurrent medications that affect potassium homeostasis (potassium supplements, potassium-sparing diuretics, NSAIDs). 4, 6
Management of Hyperkalemia Without Discontinuation
Hyperkalemia should be managed with potassium-lowering strategies rather than immediate ARB cessation:
Implement dietary potassium restriction (moderate intake, avoid high-potassium foods and salt substitutes). 4, 5, 6
Optimize or add diuretic therapy if residual renal function exists. 4, 5
Consider gastrointestinal cation exchangers (potassium binders). 4, 5
Discontinue potassium supplements and potassium-sparing diuretics. 6
Common Pitfalls to Avoid
Do not discontinue ARBs based solely on laboratory hyperkalemia without attempting management strategies first, as discontinuation is associated with worse cardiovascular and renal outcomes. 3
Do not combine ARBs with ACE inhibitors or direct renin inhibitors in dialysis patients, as dual RAS blockade increases hyperkalemia risk without added benefit. 4, 6
Do not assume that all hyperkalemia in dialysis patients is due to ARBs—evaluate dialysis adequacy (Kt/V), dietary indiscretion, and concurrent medications. 1